GlassScriptPhysician profile
Juan C Cabrera
NPI 1295742377
$11,004.49
in general payments reported to CMS, 2019-2025
33 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 91% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $636 · 2021: $1,261 · 2022: $2,102 · 2023: $2,470 · 2024: $1,898 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,789 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,789.28 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,028.19 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,406.75 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $919.34 | 2020-2025 | Caplyta |
| Alkermes, INC. | $715.55 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $520.36 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $511.04 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $501.80 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $482.93 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $424.00 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $367.08 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $325.34 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $282.34 | 2019-2021 | |
| Almatica Pharma LLC | $250.48 | 2021-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $242.03 | 2020-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $231.69 | 2021-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $206.71 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $199.34 | 2020-2023 | Adzenys Xr-Odt |
| Allergan, INC. | $187.38 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $187.02 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $164.61 | 2023-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $164.57 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $124.57 | 2021-2025 | Nuplazid |
| Grifols USA, LLC | $112.71 | 2024-2025 | Gamunex-C |
| Eisai INC. | $101.85 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $82.87 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $54.08 | 2020-2021 | |
| Alfasigma USA, INC. | $52.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $41.27 | 2022-2025 | Quviviq |
| Neuronetics, INC. | $37.16 | 2021-2022 | |
| Lilly USA, LLC | $32.87 | 2022-2023 | Amyvid |
| Indivior INC. | $17.61 | 2023 | Perseris |
| Vertical Pharmaceuticals, LLC | $16.09 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.